Grandfield & Dodd, LLC Alnylam Pharmaceuticals, Inc. Transaction History
Grandfield & Dodd, LLC
- $1.53 Billion
- Q1 2025
A detailed history of Grandfield & Dodd, LLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Grandfield & Dodd, LLC holds 3,032 shares of ALNY stock, worth $829,403. This represents 0.05% of its overall portfolio holdings.
Number of Shares
3,032
Previous 2,373
27.77%
Holding current value
$829,403
Previous $558,000
46.59%
% of portfolio
0.05%
Previous 0.04%
Shares
3 transactions
Others Institutions Holding ALNY
# of Institutions
688Shares Held
108MCall Options Held
839KPut Options Held
759K-
Capital World Investors Los Angeles, CA16.6MShares$4.54 Billion0.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.7MShares$3.48 Billion0.05% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.61 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA6.97MShares$1.91 Billion0.35% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.38MShares$1.2 Billion0.64% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $33.7B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...